PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable^®, disease targets, has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group and o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.